Mack David Henry 4

What Happened

• Mack David Henry, President & CEO and a director of PMV Pharmaceuticals (PMVP), received a grant of 744,960 derivative shares (reported as an "A" award) on 2026-03-05. The award is reported at $0.00 per share (no immediate cash paid).

Key Details

• Transaction date: 2026-03-05; Form 4 filed: 2026-03-09 (SEC Accession 0001341642-26-000002).
• Instrument: derivative award (code A) reported at $0.00 per share; total reported acquisition value $0.
• Vesting: 744,960 shares subject to vesting in 48 equal monthly installments beginning April 5, 2026 (per footnote).
• Shares owned after the transaction: not specified in the provided summary of the filing.
• No indication in this summary that shares were sold or immediately exercised — this is a grant/award, not an open-market purchase or sale.

Context

• This is a multi-year vesting award to the CEO. As a derivative grant/award, it does not represent an immediate market purchase or sale and does not necessarily signal near-term buying or selling by the insider. Check the full Form 4 on the SEC EDGAR site for the complete ownership table and any additional footnotes.